歌禮製藥-B(01672.HK)合作夥伴治療脂肪性肝炎藥物臨床試驗取得積極期中數據
歌禮製藥-B(01672.HK)公布,其戰略合作夥伴Sagimet Biosciences宣布,脂肪酸合成(酉每)(FASN)抑制劑ASC40 (Denifanstat)治療非酒精性脂肪性肝炎(NASH)患者2b期臨床試驗(FASCINATE-2)取得積極期中數據。
數據顯示,NASH各項關鍵標誌物有統計學意義上的顯著減少,包括肝臟脂肪含量、炎症和纖維化標誌物,這進一步驗證早期研究中觀察到的結果。
牛津大學訪問學者、Pinnacle研究中心醫學主任Stephen Harrison將於11月4至8日在美國華盛頓特區舉辦的美國肝病研究協會(AASLD)年會上就該研究的期中數據要點做口頭報告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.